Total Voting Rights

RNS Number : 9760D

ReNeuron Group plc

01 July 2019

 

 

1 July 2019

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Total Voting Rights

 

At 30 June 2019, the Company had 31,804,617 ordinary shares in issue, each carrying one voting right. This follows the issue of 3,000 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.

As the Company holds no ordinary shares in treasury, the figure of 31,804,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
N+1 Singer	[phone]
Aubrey Powell, Mark Taylor (Joint Broker)

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

END

 

 

TVRDMGGNKMFGLZG